Prat A - Search Results

1

Concordance among gene expression-based predictors for ER-positive breast cancer treated with adjuvant tamoxifen.

Prat A, Parker JS, Fan C, Cheang MCU, Miller LD, Bergh J, Chia SKL, Bernard PS, Nielsen TO, Ellis MJ, Carey LA, Perou CM. Prat A, et al. Ann Oncol. 2012 Nov;23(11):2866-2873. doi: 10.1093/annonc/mds080. Epub 2012 Apr 24. Ann Oncol. 2012. PMID: 22532584 Free PMC article.

2

Adjuvant chemotherapy in non-small cell lung cancer (NSCLC).

Felip E, Cedrés S, Peralta S, Prat A. Felip E, et al. Among authors: prat a. Ann Oncol. 2007 Jul;18 Suppl 9:ix143-6. doi: 10.1093/annonc/mdm309. Ann Oncol. 2007. PMID: 17631567 Free article. Review. No abstract available.

3

Nadir CA-125 concentration in the normal range as an independent prognostic factor for optimally treated advanced epithelial ovarian cancer.

Prat A, Parera M, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, Roxana I, Baselga J, Del Campo JM. Prat A, et al. Ann Oncol. 2008 Feb;19(2):327-31. doi: 10.1093/annonc/mdm495. Epub 2007 Dec 6. Ann Oncol. 2008. PMID: 18065408 Free article.

4

The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.

Prat A, Baselga J. Prat A, et al. Nat Clin Pract Oncol. 2008 Sep;5(9):531-42. doi: 10.1038/ncponc1179. Epub 2008 Jul 8. Nat Clin Pract Oncol. 2008. PMID: 18607391 Review.

5

Risk of recurrence during follow-up for optimally treated advanced epithelial ovarian cancer (EOC) with a low-level increase of serum CA-125 levels.

Prat A, Parera M, Adamo B, Peralta S, Perez-Benavente MA, Garcia A, Gil-Moreno A, Martinez-Palones JM, Baselga J, del Campo JM. Prat A, et al. Ann Oncol. 2009 Feb;20(2):294-7. doi: 10.1093/annonc/mdn601. Epub 2008 Sep 26. Ann Oncol. 2009. PMID: 18820245 Free article.

6

Mammary development meets cancer genomics.

Prat A, Perou CM. Prat A, et al. Nat Med. 2009 Aug;15(8):842-4. doi: 10.1038/nm0809-842. Nat Med. 2009. PMID: 19661985 No abstract available.

7

WITHDRAWN: Deconstructing the molecular portraits of breast cancer.

Prat A, Perou CM. Prat A, et al. Mol Oncol. 2010 Apr 14. doi: 10.1016/j.molonc.2010.04.003. Online ahead of print. Mol Oncol. 2010. PMID: 20447881 Free article. No abstract available.

8

Clinical implementation of the intrinsic subtypes of breast cancer.

Perou CM, Parker JS, Prat A, Ellis MJ, Bernard PS. Perou CM, et al. Among authors: prat a. Lancet Oncol. 2010 Aug;11(8):718-9; author reply 720-1. doi: 10.1016/S1470-2045(10)70176-5. Lancet Oncol. 2010. PMID: 20688274 No abstract available.

9

Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer.

Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, Perou CM. Prat A, et al. Breast Cancer Res. 2010;12(5):R68. doi: 10.1186/bcr2635. Epub 2010 Sep 2. Breast Cancer Res. 2010. PMID: 20813035 Free PMC article.

10

Deconstructing the molecular portraits of breast cancer.

Prat A, Perou CM. Prat A, et al. Mol Oncol. 2011 Feb;5(1):5-23. doi: 10.1016/j.molonc.2010.11.003. Epub 2010 Nov 24. Mol Oncol. 2011. PMID: 21147047 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

947 results

Search Page

Filters